位置:首页 > 产品库 > 重组含patatin样磷脂酶6蛋白
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
重组含patatin样磷脂酶6蛋白
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。

重组神经疾病靶标酯酶(NTE)蛋白
Recombinant PNPLA6
基因名:

PNPLA6


产品别名:

BNHS; LNMS; NTE; NTEMND; OMCS; SPG39; iPLA2delta; sws; PNPLA6; patatin like phospholipase domain containing 6; patatin like phospholipase domain containing 6; patatin-like phospholipase domain-containing protein 6; neuropathy target esterase; 含patatin样磷脂酶6; 神经疾病靶标酯酶(NTE);


背景信息:
Phospholipase B that deacylates intracellular phosphatidylcholine (PtdCho), generating glycerophosphocholine (GroPtdCho). This deacylation occurs at both sn-2 and sn-1 positions of PtdCho. Its specific chemical modification by certain organophosphorus (OP) compounds leads to distal axonopathy.
Tissue specificity;Expressed in brain, placenta, kidney, neuron and skeletal muscle.
Involvement in diseaseDefects in PNPLA6 are the cause of spastic paraplegia autosomal recessive type 39 (SPG39) ; also known as NTE-related motor neuron disorder (NTEMND). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG39 is associated with a motor axonopathy affecting upper and lower limbs and resulting in progressive wasting of distal upper and lower extremity muscles.
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2025